{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:23:41Z","timestamp":1784946221654,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The fibrosis-4 (FIB-4) index is the most widely used estimated formula to screen for advanced hepatic fibrosis; however, it has a considerable intermediate zone. Here, we propose an algorithm to reduce the intermediate zone and improve the diagnostic performance of screening for advanced liver fibrosis by incorporating Mac-2-binding protein glycan isomer (M2BPGi) into a FIB-4 based screening strategy in an average risk group. Four-hundred eighty-eight healthy and chronic liver disease subjects were analyzed using a 1:1 propensity score matched for age and sex. Advanced liver fibrosis (\u2265F3) was defined by magnetic resonance elastography (MRE, \u22653.6 kPa). Classification tree analysis was employed to improve diagnostic performance using a combination of the FIB-4 index and M2BPGi. The median serum M2BPGi levels of healthy subjects, patients without advanced fibrosis, and those with the condition were 0.48, 0.94, and 2.93, respectively. The area under the receiver operating characteristic (AUROC) curve of M2BPGi (0.918) for advanced fibrosis was the highest compared to those of the FIB-4 index (0.887), APRI (0.873), and AST\/ALT ratio (0.794). When M2BPGi was incorporated following the FIB-4 index, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 87.1%, 82.5%, 54.0%, and 96.4%, respectively. Moreover, 74.3% (133\/179) of cases in the intermediate zone of the FIB-4 index avoided unnecessary referrals. Two-step pathway (FIB-4 followed by M2BPGi) could reduce unnecessary referrals and\/or liver biopsies in an average-risk population.<\/jats:p>","DOI":"10.3390\/jcm9041119","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T04:01:46Z","timestamp":1586923306000},"page":"1119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population"],"prefix":"10.3390","volume":"9","author":[{"given":"Mimi","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Radiology, Hanyang University College of Medicine, Seoul 04763, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyul","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Family medicine, Hanyang University College of Medicine, Seoul 04763, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Kyeong","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hanyang University College of Medicine, Seoul 04763, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[{"name":"Centre for Digestive and Liver Diseases, Nara City Hospital, Nara 630-8305, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.15626","article-title":"Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population","volume":"51","author":"Kang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","first-page":"325","article-title":"Noninvasive assessment of liver fibrosis","volume":"53","author":"Crespo","year":"2010","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., and Kanemasa, K. (2012). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-2"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"Chalasani","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep4.1411","article-title":"Impact of Implementing a \u201cFIB-4 First\u201d Strategy on a Pathway for Patients With NAFLD Referred From Primary Care","volume":"3","author":"Davyduke","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Demir, M., Lang, S., Schlattjan, M., Drebber, U., Wedemeyer, I., Nierhoff, D., Kaul, I., Sowa, J., Canbay, A., and T\u00f6x, U. (2013). NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058360"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis","volume":"3","author":"Kuno","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00535-014-0946-y","article-title":"A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis","volume":"50","author":"Toshima","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep4.1080","article-title":"Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis","volume":"1","author":"Kamada","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e18366","DOI":"10.1097\/MD.0000000000018366","article-title":"Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis","volume":"98","author":"Nishikawa","year":"2019","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sato, S., Genda, T., Ichida, T., Amano, N., Sato, S., Murata, A., Tsuzura, H., Narita, Y., Kanemitsu, Y., and Hirano, K. (2016). Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122143"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e4679","DOI":"10.1097\/MD.0000000000004679","article-title":"A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine"},{"key":"ref_16","first-page":"74","article-title":"Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C","volume":"47","author":"Nishikawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yeh, M.-L., Dai, C.-Y., Lin, I.-H., Liang, P.-C., Hsieh, M.-H., Lin, Z.-Y., Chen, S.-C., Huang, J.-F., Chen, J.-J., and Yu, M.-L. (2019). Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220663"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e7778","DOI":"10.1097\/MD.0000000000007778","article-title":"Estimating of hepatic fat amount using MRI proton density fat fraction in a real practice setting","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00535-019-01626-1","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","volume":"55","author":"Shima","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep4.1386","article-title":"Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease","volume":"3","author":"Jiang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jmri.25868","article-title":"Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging","volume":"47","author":"Morisaka","year":"2017","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2017","journal-title":"Gut"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:44:55Z","timestamp":1760363095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["jcm9041119"],"URL":"https:\/\/doi.org\/10.3390\/jcm9041119","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}